MARKET

FATE

FATE

Fate
NASDAQ

Real-time Quotes | Nasdaq Last Sale

35.26
-1.09
-3.00%
After Hours: 35.13 -0.13 -0.37% 19:51 07/10 EDT
OPEN
36.49
PREV CLOSE
36.35
HIGH
36.70
LOW
35.14
VOLUME
712.03K
TURNOVER
--
52 WEEK HIGH
38.52
52 WEEK LOW
12.59
MARKET CAP
2.99B
P/E (TTM)
-22.4115
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FATE stock price target is 38.81 with a high estimate of 59.00 and a low estimate of 29.00.

EPS

FATE News

More
Biotech IPO Nkarta triples in debut
Seeking Alpha - Article · 12h ago
Fate's IND Application for CAR T Cell Therapy Gets FDA Nod
Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.
Zacks · 14h ago
Fate Therapeutics on go to advance CAR T candidate FT819 into the clinic
The FDA has signed off on Fate Therapeutics' (NASDAQ:FATE) IND to start clinical development of FT819, an off-the-shelf allogeneic chimeric antigen recepto
seekingalpha · 1d ago
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy
GlobeNewswire · 1d ago
Fate Therapeutics Announces FDA Clearance Of IND Application For First-ever iPSC-derived CAR T-Cell Therapy
FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus   Phase 1 Clinical Study will Evaluate FT819 for Patients with Advanced B-cell
Benzinga · 1d ago
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7)
Benzinga · 2d ago
Notable Insider Buys Last Week: Cigna, Fox, Uber And More
Insider buying can be an encouraging signal for potential investors. Some insiders took advantage of a secondary offering last week. Two chief executives also have stepped up to the buy window.
Benzinga · 06/20 20:09
Edited Transcript of FATE.OQ earnings conference call or presentation 11-May-20 9:00pm GMT
Q1 2020 Fate Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents · 06/16 02:50

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About FATE

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
More

Webull offers kinds of Fate Therapeutics Inc stock information, including NASDAQ:FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.